Abstract 1087
Background
Several lines of evidence suggest that the gut microbiome represents a novel biomarker in the era of immuno-oncology. Therefore, the prospective collection of fecal samples is now routinely included in clinical trials and acts as a new challenge for research nurses. However, little is known about patient compliance in the collection process. The objective of this study was to assess enrolment and compliance rates for fecal sample collection.
Methods
Fecal samples were prospectively collected in two academic institutions, University of Montreal Hospital and Gustave Roussy Cancer Center, using the International Human Microbiome Standards SOP Version 3 in the following groups: (1) patients with advanced non-small cell lung cancer (NSCLC) amenable to immune checkpoint inhibitors and (2) patients with early-stage NSCLC or renal cell carcinoma (RCC) at a pre-operative stage. Informed and written consent were obtained by research nurses and patient baseline characteristics were collected. Upon consent, a white opaque polypropylene pot with an anaerobic generator bag was provided to the patient, along with a document to explain the self-collection technique. Enrolment (signing of consent) and compliance (returning the sample) rates were analysed using a Chi-squared method.
Results
A total of 267 patients were eligible for the study and 252 (94%) patients with a median age of 64 agreed to sign the consent form. The enrolment rate in the study reached 96% (175/183) in patients receiving immunotherapy compared to 92% (77/84) in patients with early stage cancers undergoing surgical resection who did not receive immunotherapy (p = 0.01). Overall patient compliance was 81% (204/252). Importantly, compliance was significantly higher in the pre-immunotherapy setting (94%, 164/175) versus the pre-operative group (52%, 40/77) (p = 0.01). Furthermore, regardless of the cancer stage, women (82% or 77 patients) were more compliant than men (80% or 127 patients) (p = 0.02).
Conclusions
New tools to increase compliance and assist patients in sample collection should be developed, especially for male patients diagnosed with early stage disease who are undergoing surgery.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Bertrand Routy.
Funding
Montreal Cancer Institute.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5705 - External validation and longitudinal extension of the LIPI (Lung Immune Prognostic Index) for immunotherapy outcomes in advanced non-small cell lung cancer.
Presenter: Jakob Riedl
Session: Poster Display session 3
Resources:
Abstract
5758 - Changes of TCR Repertoire in Metastatic Renal Cell Carcinoma and Metastatic Melanoma Patients Treated with Nivolumab
Presenter: Martin Klabusay
Session: Poster Display session 3
Resources:
Abstract
1743 - Expression of MHC class I, HLA-A and HLA-B identifies immune activated breast tumors with favorable outcome
Presenter: María Del Mar Noblejas López
Session: Poster Display session 3
Resources:
Abstract
2219 - Prognostic Significance of Tumor Tissue NeuGcGM3 Ganglioside Expression and Predictive Value of Circulating Tumor Cell Count Monitoring in Patients Receiving Racotumomab Immunotherapy
Presenter: Necdet Üskent
Session: Poster Display session 3
Resources:
Abstract
2996 - Evolution of Myeloid-Derived Suppressor Cells and Objective Response Rate in Relapsed/Refractory Diffuse Large B Cell Lymphoma (R/R DLBCL) patients after receiving immunotherapy
Presenter: Carlos Jiménez Cortegana
Session: Poster Display session 3
Resources:
Abstract
2110 - A Phase Ia/Ib trial of the anti-programmed death-ligand 1 (PD-L1) human monoclonal antibody (mAb), CS1001, in patients (pts) with advanced solid tumors or lymphomas
Presenter: Lin Shen
Session: Poster Display session 3
Resources:
Abstract
3515 - Results from a randomised Phase 1/2 trial evaluating the safety and antitumour activity of anti-PD-1 (MEDI0680)/anti-PD-L1 (durvalumab) vs anti-PD-1 (nivolumab) alone in metastatic clear cell renal cell carcinoma (ccRCC)
Presenter: Martin Voss
Session: Poster Display session 3
Resources:
Abstract
3566 - Pembrolizumab in Advanced Rare Cancers
Presenter: Aung Naing
Session: Poster Display session 3
Resources:
Abstract
3567 - High clinical benefit rates of pembrolizumab in very rare sarcoma histotypes: first results of the AcSé Pembrolizumab study
Presenter: Jean-Yves Blay
Session: Poster Display session 3
Resources:
Abstract
2421 - Lenvatinib plus PD-1 blockade in advanced bile tract carcinoma.
Presenter: Jianzhen Lin
Session: Poster Display session 3
Resources:
Abstract